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Natural killer (NK) cells play a key innate role in the elim-
ination of infected or transformed cells that are no longer 
identified as self (Ljunggren and Kärre, 1990). The interac-
tion of inhibitory killer cell immunoglobulin-like receptors 
(KIRs) with HLA class I (HLA-I) molecules is important 
during NK cell development and regulates NK cell lysis of 
target cells that have down-regulated HLA-I expression or 
express different HLA-I allotypes. The highly polymorphic 
nature of both KIR and HLA-I has resulted in several studies 
linking the presence of particular KIR/HLA-I combinations 
with disease outcomes, in particular in the context of chronic 
viral infections. For example, the presence of KIR3DL1 
and certain HLA-I alleles has been associated with delayed 
progression to AIDS in HIV-infected individuals (Martin et 
al., 2007). Nevertheless, the mechanistic basis for such asso-
ciations remains unclear.
KIR3DL1 recognizes HLA-I allotypes that bear the Bw4 
motif, a region that spans residues 77–83 on the α1-helix of the 
HLA-I molecule. The crystal structure of the KIR3DL1*001–
peptide–HLA-B*57:01 complex demonstrated that KIR3DL1 
bound two regions that are highly conserved across HLA-I al-
lotypes in addition to residues within the Bw4 motif. Here, 
the interaction is ultimately dependent on the microarchitec-
ture of the Bw4 motif and the sequence of the bound peptide 
(Gumperz et al., 1995, 1997; Thananchai et al., 2007; Vivian 
et al., 2011; O’Connor et al., 2014; Saunders et al., 2015). Ad-
ditionally, there is evidence that polymorphism both within 
and outside the Bw4 motif can impact KIR3DL1 recognition 
(Gumperz et al., 1997; Thananchai et al., 2007; Sanjanwala et 
al., 2008; O’Connor et al., 2014). For instance, HLA-A*32:01, 
HLA-B*51:01, and HLA-B*58:01 generally confer robust 
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protection of target cells from lysis by KIR3DL1+ NK cells, 
whereas HLA-B*15:13 and HLA-B*27:05 have sometimes 
been associated with moderate or weak inhibitory effects, de-
spite the fact that all of these molecules are HLA-Bw4 allotypes 
(Cella et al., 1994; Litwin et al., 1994; Gumperz et al., 1995; 
Luque et al., 1996; Rojo et al., 1997; Carr et al., 2005; O’Con-
nor et al., 2007; Norman et al., 2009).
Our understanding of the hierarchical HLA-Bw4 
preferences of KIR3DL1 is further confounded by poly-
morphism within the KIR3DL1 locus. More than 100 al-
lelic variants of the KIR3DL1 gene have been described, 
phylogenetically spanning three main lineages based on the 
sequence differences across the three extracellular domains 
(D0–D1–D2) of the KIR3DL1 molecule (Norman et al., 
2009; Robinson et al., 2015). Namely, there are two diverse 
inhibitory lineages comprising KIR3DL1*005-like and 
*015-like alleles, whereas the third lineage is much more 
constrained at a population level and consists largely of the 
activating KIR3DS1*013 allele (Norman et al., 2007; Parham 
et al., 2012). KIR3DL1 polymorphism was initially associated 
with differences in cell surface expression, with allotypes such 
as KIR3DL1*001, *002, and *008 being expressed at high 
levels, *005 and *009 at lower levels, and *004 being largely 
retained intracellularly (Gardiner et al., 2001; Pando et al., 
2003; Taner et al., 2011; Mulrooney et al., 2015). KIR3DL1 
polymorphism can also affect recognition of HLA-I with 
polymorphisms at positions including 238 and 283 impact-
ing recognition of various HLA-Bw4 ligands (Carr et al., 
2005; Yawata et al., 2006; Thananchai et al., 2007; O’Connor 
et al., 2014). Similarly, recent evidence has shown enhanced 
recognition of HLA-B*44:03 by KIR3DL1*005 relative to 
KIR3DL1*001 and KIR3DL1*009 (Mulrooney et al., 2015). 
However, the molecular mechanisms underpinning these 
effects remain unclear.
Early studies correlated a subset of HLA-Bw4 allo-
types possessing Ile at position 80 with elevated protection 
from lysis by NK cells, which led to the hypothesis that 
Ile80 marked “high affinity” ligands for KIR3DL1 and even 
KIR3DS1 (Cella et al., 1994; Martin et al., 2007). This con-
cept has been used to frame subsequent studies examining 
disease progression. For example, in HIV-infected individuals, 
the presence of KIR3DL1 allotypes with high cell surface 
expression in combination with Ile80-encoding HLA-Bw4 
allotypes was associated with reduced viral replication and 
delayed progression to AIDS (Martin et al., 2007). Similarly, 
the presence of both KIR3DL1 and HLA-Bw4 allotypes 
with Ile80 was associated with an increased risk of relapse 
after autologous hematopoietic stem cell transplant for acute 
myeloid leukemia (AML) relative to patients who lacked 
Bw4 allotypes or who possessed Bw4 allotypes with Thr80 
(Marra et al., 2015). Although these genetic associations are 
broadly consistent with data showing that position 80 impacts 
recognition of HLA-Bw4 by KIR3DL1, it remains unclear 
whether Ile80 is predictive of high-affinity interactions with 
KIR3DL1. Similarly, the impact of KIR3DL1 polymorphism 
on disease outcome is ill defined. Accordingly, to characterize 
the spectrum of recognition and the functional consequences 
of given KIR3DL1 and HLA-Bw4 allotypic pairings, the in-
teractions of a range of HLA-I molecules with representa-
tives of the two inhibitory lineages of KIR3DL1, *005 and 
*015, together with a common interlineage recombinant, 
KIR3DL1*001, were compared. Using both KIR3DL1 te-
tramers and functional assays, Ile80 within the Bw4 motif was 
observed not to define a high-affinity ligand for KIR3DL1. 
Instead, distinct hierarchies were detected for each KIR3DL1 
allotype that assist in reconciling the influence of both 
KIR3DL1 allotype and HLA-Bw4 polymorphism in deter-
mining effective inhibitory capacity. From the ternary crystal 
structures of KIR3DL1*001, *005, and *015, we show that 
the dimorphism at position 283 alters the configuration of 
D1–D2, leading to increased flexibility in KIR3DL1*005, 
which confers a distinct but broader specificity for HLA-Bw4 
allotypes. Our data provide a molecular framework to inter-
pret the impact of KIR3DL1 polymorphism on HLA-I rec-
ognition and can be used to inform disease association studies.
RES ULTS
KIR3DL1+ NK cells differentiate 
between HLA-Bw4 molecules
Although numerous studies have shown that KIR3DL1 in-
teractions with HLA-Bw4 allotypes inhibit NK cell acti-
vation, the extent to which this varies between individuals 
and different HLA-I allotypes has remained unclear (Cella et 
al., 1994; Gumperz et al., 1995, 1997). To address this issue, 
KIR3DL1+ NK cells obtained from several healthy donors 
were expanded with IL-2 and then incubated either with 
721.221 (221) cells, which lack endogenous HLA-A, -B, and 
-C, or 221 cells transfected with a range of HLA-I molecules: 
HLA-B*57:01, -B*58:01, and -A*24:02, which all encode an 
identical Bw4 motif (NLR IALR), HLA-B*27:05 and HLA-
B*44:05, which encode distinct Bw4 motifs containing a Thr 
at position 80, and HLA-B*08:01, a control allotype that pos-
sesses the Bw6 motif (Fig. 1, A and B). The up-regulation of 
CD107a, a marker for degranulation, was assessed by flow 
cytometry and normalized against the maximal response to 
the parental 221 cell line (Fig. 1, C and D).
HLA-B*44:05, HLA-B*57:01, and HLA-B*58:01 
efficiently inhibited KIR3DL1+ NK cells, whereas HLA-
A*24:02 and HLA-B*27:05 were more limited in this regard, 
often showing comparable levels of activation with those ob-
served with target cells expressing HLA-B*08:01 (Fig. 1, C 
and D). These inhibitory effects were not caused by CD94-
NKG2A recognition of HLA-E on the cell surface because 
all assays were performed in the presence of a CD94-blocking 
antibody (Pende et al., 2009). In line with this, the pattern 
of inhibition of was not consistent with a CD94-NKG2A/
HLA-E–dependent mechanism as HLA-B*08:01– and HLA-
A*24:02–derived leader sequence peptides (residues 3–11) 
form more potent CD94-NKG2A ligands when complexed 
with HLA-E than those derived from other Bw4 allotypes 
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(Borrego et al., 1998; Brooks et al., 1999; Petrie et al., 2008). 
Moreover, variation in the capacity of different HLA-I allo-
types to inhibit CD107a expression did not correlate with 
the level of expression of the transfected HLA-I molecules 
(Fig.  1 E). Notably, of the cells expressing HLA-Bw4 allo-
types, the 221.B5801 transfectants displayed the lowest cell 
surface expression levels yet had among the most potent in-
hibitory capacity (Fig.  1, D and E). Similarly, although the 
expression of HLA-B*27:05 was higher than any other al-
lotype, there was little evidence of Bw4-dependent inhibi-
tion of KIR3DL1+ NK cell activation (Fig. 1 D). Possession 
of Thr80 did not correlate with poor inhibition, as HLA-
B*44:05 (Thr80) efficiently inhibited KIR3DL1+ NK cells. 
Similarly, the presence of Ile80 did not strictly correlate with 
potent inhibition as although HLA-B*57:01 and -B*58:01 
conferred robust inhibition, HLA-A*24:02 was a poor inhib-
Figure 1. Inhibition of KIR3DL1+ NK cells 
varies with HLA-Bw4 expressing targets. 
(A) Amino acid sequences across residues 77–83 
of transfected HLA-I molecules. (B) The surface ex-
pression of transfected HLA-I molecules was con-
firmed by staining with W6/32 (gray histograms) 
or anti-Bw4 (black histograms) mAbs followed 
by anti–mouse IgG-FITC. Filled gray histograms 
represent background staining with secondary 
antibody alone. (C and D) KIR3DL1+ NK cells were 
sorted from eight donors and expanded with IL-2. 
Equal numbers of KIR3DL1+ NK cells and 221 
transfected target cells were cultured with the ad-
dition of anti-CD107a for 4 h in the presence of 
monensin. CD107a expression was then examined 
by flow cytometry, gating on CD56+/NKB1+ cells. 
(C) Representative flow cytometric plots showing 
CD107a expression. Values indicate the percentage 
of cells expressing CD107a. (D) Normalized CD107a 
expression after co-culture of KIR3DL1+ NK cells 
with transfected or parental 221 cells where the 
response to untransfected 221 cells was adjusted 
to 100%. Horizontal lines indicate mean. Data 
are pooled from six independent experiments. 
(E) The MFI of W6/32 versus the MFI of subsequent 
CD107a expression is plotted for each 221 trans-
fectant for a representative donor.
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itory ligand (Fig. 1 D). Additionally, analyses of the capacity of 
KIR3DL1+ NK cells to degranulate directly ex vivo revealed 
a similar pattern of reactivity. Specifically, HLA-B*57:01 
was markedly more inhibitory than allotypes such as HLA-
A*24:02, indicating that the variation in inhibitory capacity 
of different HLA-I allotypes was not simply attributable to 
the use of in vitro–activated NK cells (not depicted). Thus, 
different HLA-Bw4 molecules displayed variable inhibitory 
capacities between KIR3DL1+ donors that were not closely 
correlated with the Ile/Thr dimorphism at position 80. Fur-
thermore, the extent to which distinct HLA-I allotypes, in 
particular HLA-A*24:02 and HLA-B*27:05, inhibited de-
granulation of KIR3DL1+ NK cells varied markedly between 
donors and suggested that allotypic differences in KIR3DL1 
also influenced ligand recognition.
KIR3DL1 allotypes demonstrate distinct 
hierarchies of HLA-Bw4 interaction
To account for the impact of KIR3DL1 polymorphism on 
HLA-Bw4 recognition and to generate a broader perspec-
tive on KIR3DL1–HLA-I binding combinations, soluble 
KIR3DL1*005, *015, and *001 proteins were produced 
and used to create fluorescently labeled KIR3DL1 tetram-
ers. These KIR3DL1 tetramers were then assessed for their 
ability to bind an extensive panel of bead-bound HLA-I 
molecules comprising 100 distinct allotypes. The 25 HLA-I 
molecules recognized most strongly by KIR3DL1*015 
were then ranked and compared against KIR3DL1*001 
and KIR3DL1*005. All three KIR3DL1 tetramers displayed 
a strong preference for HLA-Bw4 molecules (Fig.  2  A). 
For example, 19 of the top 25 HLA-I allotypes bound by 
KIR3DL1*015 were HLA-Bw4 molecules (Fig. 2, B and C). 
Weak binding was observed to the HLA-C molecules HLA-
C*07:02, -C*04:01, -C*01:02, and -C*16:01 (up to 12.7% 
of the maximum signal for KIR3DL1*015 binding to HLA-
C*04:01; Fig. 2, B and C). In contrast, there was negligible 
binding to HLA-A allotypes, such as HLA-A*02:01, which 
lacked the Bw4 motif (not depicted). Importantly, the recog-
nition patterns seen in this assay matched well with the data 
from our degranulation assays where strong recognition of 
HLA-B*57:01 and B*58:01 allomorphs and weaker recogni-
tion of HLA-B*27:05 was observed for all three KIR3DL1 
allotypes tested (Fig. 2, A and C).
Each of the KIR3DL1 proteins displayed distinct hi-
erarchical preferences for HLA-Bw4 allomorphs, with 
KIR3DL1*005 being the most divergent. Although 
KIR3DL1*001 and *015 exhibited a broadly similar pref-
erence for HLA-Bw4 allomorphs, differences were ap-
parent (Fig.  2, A–C). For example, KIR3DL1*001 bound 
more strongly than KIR3DL1*015 to several HLA-Bw4 
allomorphs, including HLA-B*44:03 and HLA-B*57:03. 
Moreover, KIR3DL1*001 bound HLA-B*57:01 and HLA-
B*57:03 with similar intensity, whereas KIR3DL1*015 
preferentially bound HLA-B*57:01 in comparison with 
HLA-B*57:03. Thus, there were clear differences between 
KIR3DL1*001 and *015 in terms of relative binding strength 
across different HLA-Bw4 allomorphs and ultimately in 
the rank order of binding.
Although KIR3DL1*005 bound HLA-I allotypes 
such as HLA-B*57:01 and HLA-B*58:01 with high avid-
ity, there were several significant changes in both the rank 
order of binding and ligand specificity in comparison with 
both KIR3DL1*001 and KIR3DL1*015 (Fig. 2, B and C). 
For example, KIR3DL1*001 and *015 bound HLA-A*32:01 
very strongly, yet there was only a weak interaction with 
HLA-A*24:02. In contrast, the binding of KIR3DL1*005 to 
HLA-A*24:02 and HLA-A*32:01 was equivalent, indicating 
broader recognition of HLA-A allomorphs possessing the 
Bw4 motif (Fig. 2 C). Additionally, there was substantial vari-
ation in KIR3DL1 binding to certain HLA-B allotypes, most 
notably HLA-B*44:02 and -B*44:03, the former of which 
was ranked second for KIR3DL1*005 binding, yet interacted 
relatively poorly with *001 and *015. This overall compar-
ison against KIR3DL1*001 and *015 shows that *005 has 
both broader and distinct preference for HLA-Bw4 ligands.
This broad screening approach allowed the impact of 
the Ile/Thr dimorphism at position 80 of HLA-Bw4 allo-
types on KIR3DL1 binding to be reexamined (Fig. 2, B and 
C). When viewed as a group, Ile80+ allotypes preferentially 
interacted with both KIR3DL1*001 and *015 relative to the 
Thr80+ allotypes (Fig.  2, A and B). Nevertheless, the pres-
ence of Ile80 did not strictly correlate with strong binding 
to either KIR3DL1*001 or *015 because HLA-A*24:03 
and -B*52:01 (Ile80) interacted more weakly than HLA-
B*44:03 and HLA-B*47:01 (Thr80; Fig. 2, A and C). In con-
trast, there were no significant differences in the ability of 
KIR3DL1*005 to discriminate between allotypes that con-
tain Ile80 and Thr80 (Fig. 2 B). These data reveal substantial 
variation in the specificity between KIR3DL1 allotypes, with 
KIR3DL1*005 being the most permissive allotype across the 
range of HLA-Bw4 molecules. Moreover, the Ile80/Thr80 
dimorphism of HLA-Bw4 allotypes is not predictive of the 
strength of ligand recognition by KIR3DL1.
Differences in HLA-Bw4–mediated inhibition between 
KIR3DL1+ NK cell clones
Although the interaction of KIR3DL1 tetramers to beads 
coated with individual HLA-I allotypes generated binding 
hierarchies for KIR3DL1*005, *015, and *001, it was unclear 
whether these reflected functional differences. Consequently, 
a panel of NK clones from donors of known KIR3DL1 al-
lotype, LM (KIR3DL1*001), RM (KIR3DL1*002 and 
*00501), and BC (KIR3DL1*00501), were generated, with 
the KIR3DL1*002 and *005 populations of donor RM iso-
lated by sorting DX9hi and DX9lo NK cells, respectively (not 
depicted). KIR3DL1*002 belongs to the *015 lineage, dif-
fering from KIR3DL1*015 only at position 238 within the 
D2 domain (Fig. 3 A). These clones were then assessed for 
their capacity to lyse either 221 cells or 221 cells transfected 
with different HLA-I allotypes. Consistent with both their 
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Figure 2. Tetramers of each KIR3DL1 allomorph display distinct binding preferences to HLA-I–coated beads. (A) The fluorescent values for the top 
25 HLA alleles binding to each KIR3DL1 allotype in the HLA-I bead assay are shown as normalized values for KIR3DL1*015, KIR3DL1*001, and KIR3DL1*005. 
HLAs are categorized by percentage maximum binding with 100–75% maximum binding (red), 75–50% maximum binding (pink), 50–25% maximum 
binding (gray), and 25–0% binding (teal). (B) KIR3DL1 allotype recognition for all HLA-Bw4–containing allomorphs present on the bead assay is plotted 
KIR3DL1 polymorphism and HLA class I recognition | Saunders et al.796
superior capacity to bind KIR3DL1 tetramers (Fig. 2 C) and 
to inhibit the activation of polyclonal NK cells (Fig. 1 D), the 
expression of HLA-B*57:01 and HLA-B*58:01 conferred 
protection from all KIR3DL1+ NK cell clones assessed, re-
gardless of KIR3DL1 allotype (Fig. 3 B). This protection was 
mediated in part through KIR3DL1, as indicated by the in-
creased lysis after addition of the KIR3DL1/S1-specific an-
tibody, Z27. Similarly, the expression of HLA-B*44:05 also 
conferred substantial target cell protection irrespective of 
KIR allotype, again reflecting our observations in assays of 
bulk NK cell cultures (Figs. 1 D and 3 B).
In contrast, NK cell clones expressing either 
KIR3DL1*001 or KIR3DL1*002 readily lysed 221 cells ex-
pressing HLA-A*24:02, whereas the same HLA-I allotype 
conferred protection from clones expressing KIR3DL1*005 
(Fig.  3  B). The extent of this inhibition varied between 
KIR3DL1*005+ donors, with donor BC exhibiting ∼40% 
maximum lysis compared with donor RM at 18%. The pat-
tern of reactivity of NK cell clones toward target cells ex-
pressing HLA-B*27:05 was similar to those that expressed 
HLA-A*24:02, in that although HLA-B*27:05 did not confer 
significant protection from clones expressing KIR3DL1*002, 
it nevertheless conferred significant protection from lysis by 
clones from donor RM that expressed the *005 allotype. 
This broadly reflected what was observed in the KIR3DL1 
tetramer binding assay because KIR3DL1*005 bound to 
both HLA-A*24:02– and HLA-B*27:05–coated beads more 
strongly than the other KIR3DL1 allotypes, albeit with weaker 
avidity than was observed for HLA-B*57:01, -B*58:01, and 
-B*44:02. Nevertheless, the binding of KIR3DL1*005 to 
HLA-B*27:05 was still stronger than that to any non-Bw4 
allotype. Collectively, the functional and bead binding data 
suggest that although HLA-B*27:05 may interact with 
KIR3DL1*005 with low avidity, it is still able to function as 
a ligand. In contrast, KIR3DL1*001 and *015-lineage mol-
ecules appear to have a higher binding threshold for func-
tional ligand recognition.
To confirm and extend these analyses, an additional 
panel of clones was established from another four donors. The 
KIR3DL1 allele expressed in each clone was determined by 
sequencing KIR3DL1 cDNAs amplified from RNA, identi-
fying clones expressing KIR3DL1*005 and *015, as well as 
KIR3DL1*002 and *009. Uniquely, KIR3DL1*009 possesses 
the D0 domain of KIR3DS1 coupled with the *001 D1–D2 
domains (Fig. 3 A) and has been suggested to display weaker 
binding to HLA-Bw4 than KIR3DL1*001 or *005 (Mul-
rooney et al., 2015). These NK cell clones were then cocul-
tured with either parental or HLA-I–transfected 221 cells, and 
the expression of CD107a was assessed by flow cytometry. The 
expression of CD107a by KIR3DL1*001+, *002+, and *005+ 
NK clones was consistent with the data obtained from the 
cytotoxicity assays (Fig. 3 C). Namely, HLA-B*57:01, HLA-
B*58:01, and HLA-B*44:05 effectively inhibited degranula-
tion by all KIR3DL1 allotypes tested, whereas HLA-A*24:02 
only inhibited activation of the KIR3DL1*005+ clone. Both 
KIR3DL1*015 and *009 resembled KIR3DL1*001 in their 
recognition of HLA-B*57:01, HLA-B*58:01, and HLA-
B*44:05, where all three HLA-I allotypes inhibited CD107a 
expression. In contrast, the expression of HLA-A*24:02 had 
only a modest inhibitory impact on degranulation of NK cell 
clones expressing KIR3DL1*001, *002, *015, and *009. Col-
lectively, the data derived from the analyses of 35 NK clones 
derived from seven donors expressing a range of KIR3DL1 
allotypes have identified clear specificity differences between 
KIR3DL1*005, and several KIR3DL1 allotypes that share 
common polymorphisms across the D1 and D2 domains, no-
tably residues 182 and 283. The data highlight that the Bw4 
recognition preferences of KIR3DL1 do not simply segregate 
with the presence of an Ile or Thr at position 80. Moreover, 
the data suggest that KIR3DL1*005 has an expanded ligand 
range relative to allotypes of the KIR3DL1*015 lineage or 
the recombinant allotypes KIR3DL1*001 and *009. Accord-
ingly, there is a functional hierarchy of HLA-Bw4 recognition 
that is dependent on KIR3DL1 polymorphism.
Molecular basis of KIR3DL1 
polymorphism on HLA-I recognition
To provide molecular insights into the altered patterns of ligand 
recognition by KIR3DL1*001, *005, and *015, the structures 
of KIR3DL1*005 and *015 in complex with HLA-B*57:01 
were determined to 2.3 and 2.5 Å, respectively (Table 1). The 
KIR3DL1 complexes were crystallized in the same condi-
tions and in the same space group (Table 1). The high quality 
of the resultant structures allowed for direct comparison with 
the previously determined KIR3DL1*001–peptide–HLA-
B*57:01 complex (Vivian et al., 2011). The overall binding 
mode of these three KIR3DL1–peptide–HLA-I ternary 
complexes was similar. Specifically, the D0 domain clamped 
around the side of HLA-B*57:01, abutting β2-microglobulin, 
whereas the D1 and D2 domains were positioned above the 
C-terminal end of the peptide-binding cleft, with the D1 do-
main interacting with the Bw4 motif (Fig. 4, A and B). The 
and separated by dimorphism at position 80 (80I and 80T). Binding values are given as normalized binding (top) and MFIs (bottom). Significant differences 
between Bw4 80I and Bw4 80T subtype recognition as measured by independent multiple Student’s t tests are shown with an asterisk. The p-value for 
KIR3DL1*001 is 0.016 and that for KIR3DL1*015 is 0.019, whereas the nonsignificant value for KIR3DL1*005 is 0.143. (C) HLA-I alleles on the bead assay are 
ranked by recognition of KIR3DL1*015, and the top 28 alleles are depicted with comparison of rank and binding values for these alleles with those for the 
KIR3DL1*001 and *005 allotypes. HLAs are shown by rank (left) and percentage (right) of highest binding allele. All data represent mean values from three 
independent experiments. Error bars depict one standard deviation from the mean value. Shading is a three-color conditional formatting scale. A percentage 
of maximum binding value of 0 is assigned blue and that of 100 is assigned red, and the 50th percentile is colored light pink.
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Figure 3. KIR3DL1 molecules of different lineages functionally discriminate between HLA-Bw4 ligands. (A) The polymorphic residues found in 
KIR3DL1*015, *002, *001, *009, *005, and *004 (and the KIR3DS1 lineage) are shown, with additional residues of variance also noted (list is not exhaustive). 
(B) KIR3DL1+ NKG2A− cells were sorted and cloned from three healthy volunteers of known KIR3DL1 allotype (LM *001; RM *002/*00501; BC *00501). Cloned 
NK cells were then incubated with 51Cr-labeled 221 transfectants at the indicated E:T ratios in the presence or absence of anti-KIR3DL1/S1 mAb (Z27). Data 
shown are mean cytotoxicity ± SEM, where the response to untransfected 221 cells was adjusted to 100%, based on the maximal cytotoxicity observed 
in the presence of parental 221 targets and in the absence of Z27. The number of clones individually assessed at the given ratios is noted in parentheses. 
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KIR3DL1*005 and *015 complexes maintained key contacts 
with HLA-B*57:01 that were identified from structural and 
mutagenesis studies of KIR3DL1*001 recognition (Vivian 
et al., 2011). In particular, the interactions between positions 
Phe9 on the D0 domain and residues 17–19 on HLA-B*57:01 
and the interactions between Tyr200, Phe276, and Glu282 on 
the D2 domain and residue Lys146 on the α2 helix of HLA-
B*57:01 were conserved (Fig.  4  B). Similarly, the contacts 
between the KIR3DL1 residue Leu166 and Ile80 in the Bw4 
motif and Ser8 in the bound peptide were preserved across 
all KIR3DL1 ternary complexes (Fig. 4 B). The total buried 
surface area at the complex interfaces was also comparable, 
(KIR3DL1*001 = 1,790 Å2, *005 = 1,870 Å2, and *015 = 
2,060 Å2). Accordingly, the three KIR3DL1 allomorphs use 
a similar inventory of principal residues to recognize HLA-
B*57:01 complexed with the LSS PVT KSF (LF9) peptide.
Despite this consensus docking mode, differences were 
observed between the three ternary complexes attributable to 
polymorphic residues that distinguish KIR3DL1*001, *005, 
and *015. KIR3DL1*005 and *015 differ at seven amino 
acids, five in the signal sequence–D0 domain and two in 
the D1–D2 domains. Across the extracellular regions exam-
ined, KIR3DL1*015 differs from *005 at positions Val47Ile, 
Leu54Ile, Pro182Ser, and Trp283Leu. As KIR3DL1*001 is 
a recombinant of the D0 from *005 and the D1–D2 from 
*015, it thus differs from *015 at positions 47 and 54 and 
from *005 at positions 182 and 283 (Fig. 4 A).
The docking of the D0 and D1 domains to HLA-
B*57:01-LF9 was distinct between the complexes, despite a 
common 80° hinge angle about the D0–D1 domains (Fig. 4, 
C and D). Notably, the KIR3DL1*005 D0–D1 domain ar-
rangement was identical to that observed in *015, both of 
which were distinct from that of *001. More specifically, com-
pared with the KIR3DL1*001 complex, the *005 and *015 
complexes displayed a 3° difference in the crossing angle of 
the D1 domain and a 1-Å translational shift of the D0 domain. 
These two D0–D1 profiles were coincident with two distinct 
conformations of the C–C′ loop (Fig.  5  A). Such confor-
mations were also observed in complexes of KIR3DL1*001 
with HLA-B*57:01 bound to different peptides (unpublished 
data). Thus, the C–C′ loop conformation varies as a function 
of both the bound peptide and the KIR3DL1 allotype.
The hinge angle between the D1 and D2 domains 
clearly distinguished the KIR3DL1*001 and *015 com-
plexes from that of *005. This angle in KIR3DL1*001 and 
*015 was more acute (76°) than that observed in *005 (80°; 
Fig. 4, C and D). Centrally placed to influence the interdo-
main hinge angle was the dimorphic residue 283, residing on 
the F′ strand of the D2 domain, interconnecting the D1 and 
D2 domains. Trp283 in KIR3DL1*001 and *015 and Leu283 
in *005 were positioned in a hydrophobic pocket and made 
similar contacts to neighboring residues, including contacts to 
Leu112 and Val195 on the D1 domain and His233, Phe273, 
and Ser275 on the D2 domain (Fig. 5, B and D). Unique to 
Trp283 was an H-bond from the indole nitrogen to Pro280 
that aided the alignment of Trp283. These contacts were of 
importance to the hinge angle, with Trp283 oriented parallel 
to the axis of the D1–D2 hinge. Trp283 therefore had a nar-
rower profile than Leu283, allowing for a tighter hinge angle 
(Fig. 4 C and Fig. 5, B and D).
The differences in the relative angles of the KIR3DL1 
domains had a modest impact on contacts with HLA-
B*57:01–LF9. Indeed, all contacts were preserved to residues 
known to be critical for the interaction with KIR3DL1*001 
(Vivian et al., 2011). However, differences were observed 
at the short helix between the E–F strands, as Met165 on 
KIR3DL1*005/*015 formed an additional peptide con-
tact to Thr6. Furthermore, the 8° difference in the cross-
ing-angle of the D2 domain (Fig.  4, C and D) enabled 
additional contacts between the F-strand residue His278 on 
KIR3DL1*001/*015 and Ile142 and Tyr84 of the HLA mol-
ecule (Fig. 5 C). Combined with the wider hinge angle for 
the D1–D2 domains of KIR3DL1*005, this translates to a 
different docking mode for the *005 allotype, which further 
associates with an impact on HLA-Bw4 recognition.
Increased mobility of ligand-binding 
loops within KIR3DL1*005
We hypothesized that the wider D1–D2 angle in 
KIR3DL1*005 relative to either *001 or *015 would con-
fer a greater degree of flexibility around the peptide–HLA-I 
binding site, thereby allowing KIR3DL1*005 to tolerate 
a broader range of ligands. To test this hypothesis, solution 
phase deuterium exchange experiments were performed on 
KIR3DL1*001, *015, and *005. In these experiments, in-
creased levels of hydrogen exchange with deuterium were 
associated with a greater degree of mobility. Strikingly, mass 
spectrometric analysis showed that the greatest difference 
in the extent of deuterium exchange was located within 
ligand-binding loops of KIR3DL1 (Fig. 6, A–C). These loops 
were the D1 C–C′ loop (residues 133–145; Fig.  6  A), the 
D1 E–F loop (residues 160–173; Fig. 6 B), and the D1–D2 
hinge loop (residues 194–205; Fig. 6 C). Moreover, in each 
case, there was significantly more deuterium exchange in 
Data shown are pooled from six independent experiments. (C) PBMCs were isolated from unknown donors, KIR3DL1+ cells were sorted and cloned, and 
the KIR3DL1 alleles were sequenced. Expanded NK clones were incubated with 221 transfectants at a 1:1 ratio with the addition of a CD94-specific block-
ing mAb Y9, along with anti-CD107a, followed by monensin. After 4-h incubation, cells were stained for CD56 and KIR3DL1, and CD107a expression was 
assessed by flow cytometry. Experiments were performed once for each clone with the CD107a expression normalized to the maximal CD107a expression 
observed after co-culture in the presence of untransfected 221 cells. Plot shows mean CD107a expression ± SEM with the number of clones assessed noted 
in parentheses. Data were pooled from five independent experiments.
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KIR3DL1*005 relative to *001 or *015 (Fig. 6, A–C). The 
extent of exchange in the latter two allotypes was similar. 
Deuterium exchange data were also collected on peptide 
fragments from the D2 C–C′–D strands and the D–E loop 
(residues 233–253; Fig. 6 D), the D2 E–F loop and F-strand 
(residues 260–274; Fig. 6 E), and the D2 F–F′ and F′–G loops 
(residues 275–292; Fig. 6 F). For each of these D2 peptide 
fragments, there was no difference in the extent of deuterium 
exchange. Collectively, these data show that the ligand-binding 
loops of the D1 and the D1–D2 hinge loop of KIR3DL1*005 
are more dynamic than either *001 or *015, suggesting that 
the wider hinge angle ultimately allows the *005 allotype to 
adopt conformations that can accommodate microvariation 
in ligand structure resulting from both HLA-I polymorphism 
and variability in the associated peptide repertoire.
DIS CUS SION
High-avidity interactions between inhibitory KIRs and their 
HLA-I ligands are thought to result in well-educated NK 
cells with potent effector functions that are highly respon-
sive to cells with reduced surface expression of HLA-I. Such 
interactions have been proposed to be associated with poor 
outcomes in malignancies such as AML, where there is lit-
tle evidence of HLA-I down-regulation, and with improved 
viral control in HIV-infected individuals (Cooley et al., 2014; 
Marra et al., 2015). However, the molecular signatures that 
define “high-affinity” interactions are themselves poorly de-
fined. Specifically with respect to KIR3DL1, the presence 
of an Ile80 within the Bw4 motif has been thought to act 
as a signature for potent ligands, particularly for KIR3DL1 
allotypes with high levels of cell surface expression, which 
ultimately translated into clinical associations with disease 
progression in the setting of HIV (Cella et al., 2000; Yawata 
et al., 2006; Martin et al., 2007). Several studies following a 
similar approach have found associations between the pres-
ence of KIR3DL1 and Bw480I allotypes with the probability 
of relapse in patients receiving hematopoietic stem cell trans-
plantation for AML or simply with the presence of Bw480I 
in diseases such as Behçet’s disease and hepatitis B–associated 
hepatocellular carcinoma, often in association with KIR3DS1 
(Pan et al., 2011; Kuranov et al., 2014; Marra et al., 2015). 
Although residue 80 clearly plays a central role in KIR3DL1 
recognition, the functional and binding data presented here 
demonstrate that the presence of Ile80 alone is insufficient for 
strong engagement of KIR3DL1. Notably, there were marked 
differences between different Ile80+ Bw4 allotypes in terms of 
their capacity to inhibit target cell lysis by clonal or polyclonal 
KIR3DL1+ NK cells. For example, although HLA-B*57:01 
and HLA-B*58:01 readily conferred protection from lysis by 
KIR3DL1+ NK cells, HLA-A*24:02 exhibited considerably 
Table 1. Refinement statist ics for KIR3DL1*005 and KIR3DL1*015
Statistics KIR3DL1*005–HLA-B*57:01–LF9 KIR3DL1*015–HLA-B*57:01–LF9
Data collection statistics
Temperature (K) 100 100
X-ray source MX2 Australian synchrotron MX2 Australian synchrotron
Space group P1 P1
Cell dimensions a = 51.6, b = 61.3, c = 66.4 α = 95.2, β = 100.2, γ = 108.2 a = 51.6, b = 61.1, c = 65.1, α = 95.6, β = 98.5 γ = 108.6
Resolution (Å) 50–2.30 (2.42–2.30) 50–2.5 (2.64–2.50)
Total no. observations 139,081 (20,784) 99,352 (14,846)
No. unique observations 30,955 (4,571) 23,125 (3,419)
Multiplicity 4.5 (4.5) 4.3 (4.3)
Data completeness (%) 92.9 (95.0) 90.7 (91.5)
1/σI 6.9 (3.6) 7.3 (3.7)








Bond lengths (Å) 0.003 0.005
Bond angles (°) 0.702 0.874
Ramachandran plot
Favored regions (%) 95.0 95.4
Allowed regions (%) 5.0 4.6
B-factors
Mean main chain (Å2) 34 32
Mean side chain (Å2) 38 37
Mean water (Å2) 38 36
aRmerge = ∑hkl ∑j|Ihkl,j − <Ihkl>|/∑hkl ∑j Ihkl,j.
bRfactor = ∑hkl||Fo| − |Fc||/∑hkl|Fo| for all data excluding the 5% that comprised the Rfree used for cross-validation.
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weaker effects, despite the fact that all three HLA-I allotypes 
shared an identical sequence spanning the Bw4 motif. Ex-
tending these functional observations, our broad screening 
of HLA-I binding preferences using KIR3DL1 tetramers 
showed that although Bw4 molecules possessing Ile80 were 
among the best ligands regardless of KIR3DL1 allotype, sev-
eral Ile80+ allotypes such as HLA-A*23:01, HLA-A*24:02, 
and HLA-B*52:01 were poorly recognized. Indeed, these 
allotypes were weaker ligands than HLA-B*44:02, HLA-
B*44:03, and HLA-B*47:01, all of which encode Thr80. 
Thus, although many potent ligands possess Ile80, the Ile/Thr 
dimorphism at residue 80 cannot strictly be used as a marker 
of KIR3DL1 ligand affinity. This has important implications 
for disease association studies based around the presence or 
absence of Bw4 allotypes that have Ile80. The majority of 
Bw480I alleles that act as high-avidity ligands for KIR3DL1 
are themselves relatively common, at least in certain ethnic-
ities. For example, the overall frequency of HLA-B*57:01 is 
typically reported to vary between 1 and 3% in most stud-
ies but may be significantly higher in those of Indian de-
cent, whereas the overall frequency of HLA-B*58:01 is ∼3% 
and can be very common in African populations (Cao et al., 
2001; Solberg et al., 2008). However, we have shown that 
other Bw480I alleles such as HLA-A*24:02 and -B*52:01, 
both of which can be very common (>5%) in certain Asian 
populations, can be relatively poor ligands, at least for certain 
KIR3DL1 allotypes (Cao et al., 2001; Solberg et al., 2008). 
The inclusion of the latter alleles into groups of alleles that 
are considered to be high avidity/function may mean the 
strength of the associations reported with diseases in HIV and 
AML are underestimated. Similarly, the exclusion of common 
Bw480T allotypes such as HLA-B*44:03 that interact robustly 
with KIR3DL1*015, *001, and *005 may also serve to di-
minish the statistical strength of these disease associations. As 
Figure 4. Structural comparison of 
KIR3DL1 allomorphs in complex with 
HLA-B*57:01. (A) The location of the poly-
morphic differences between KIR3DL1*001, 
*005, and *015 mapped onto the structure of 
KIR3DL1*005 in complex with HLA-B*57:01. 
(B) The primary contacts between the KIR3DL1 
(cyan) and HLA-B*57:01. The Bw4 motif on 
the α1 helix and Lys146 on the α2 helix are 
shown as yellow sticks. The peptide is shown 
as pink sticks. (C and D) Docking of KIR3DL1 
allotypes onto HLA-B*57:01–LF9. The axes of 
inertia of each of the KIR3DL1 domains are 
shown as rods. KIR3DL1*001 is colored or-
ange, *005 is colored cyan, and *015 is col-
ored yellow. The hinge angles between the 
domains are shown in C and the crossing an-
gles of the domains in D.
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such, the data here provide an empirical rationale for the re-
evaluation of disease association studies that are genuinely 
based on the avidity of the KIR3DL1/ligand.
Further compounding the difficulty of interpreting as-
sociations of KIR3DL1 and Bw4 alleles with clinical out-
comes is allelic variation in KIR3DL1 itself. Our data, based 
on the binding of KIR3DL1 allotypes representative of the 
two major inhibitory allelic lineages (*015 and *005) along 
with an interlineage recombinant (*001), systematically eval-
uated the extent to which allotypic variation in KIR3DL1 
modulates receptor specificity. Notably, KIR3DL1*015 
bound to its ligands with lower avidity than either *001 
or *005. Moreover, the polymorphic differences between 
KIR3DL1*001 and *015 did not simply impact the over-
all level of binding but rather resulted in subtle differences 
in the specificity between KIR3DL1*015 and *001. More 
striking still were the differences in binding profile between 
KIR3DL1*005 and both KIR3DL1*001 and *015. Not only 
did KIR3DL1*005 bind a greater range of HLA-I allotypes, 
but there were also marked differences in the hierarchy of 
HLA-I allotype binding. When assessed in functional assays 
using NK cell clones, the altered binding hierarchy between 
different KIR3DL1 allotypes was manifest in an altered 
specificity. Namely, a larger spectrum of HLA-I allotypes 
were able to inhibit activation of NK cell clones expressing 
KIR3DL1*005 compared with other allotypes examined, in-
cluding KIR3DL1*001, *015, *009, and *002.
Previous findings had suggested that the Trp/Leu di-
morphism at residue 283 of KIR3DL1 was critical in de-
fining the *015 and *005 lineages of KIR3DL1 and show 
that the introduction of Leu283 in KIR3DL1*001, *007, and 
*015 enhanced binding to Bw4 tetramers possessing Thr80 
(Sharma et al., 2009; O’Connor et al., 2014). Here we show 
that KIR3DL1 allotypes possessing Trp283 had a more re-
stricted range of ligands as assessed by both binding and func-
tional experiments than KIR3DL1*005, which possesses a 
Leu at this position. The differences between KIR3DL1*015, 
*001, and *005 center on a limited set of dimorphic resi-
dues: residues 2, 47, and 54 on the D0 domain (distal to the 
HLA binding interface), residue 182 on the D1 domain (at 
the D0–D1 domain interface), and residue 283 (at the D1–
D2 domain interface). Sharma et al. (2009) have shown that 
KIR3DL1*001 bound more strongly to HLA-A*24:02 te-
tramers complexed with a nef-encoded peptide than either 
KIR3DL1*005 or KIR3DL1*015, suggesting some degree 
of synergy between the D0 and D1–D2 domains in the re-
combinant allele. However, given that ligand recognition 
by KIR3DL1 is acutely dependent on the sequence of the 
Figure 5. Structural details underpinning 
the differences between KIR3DL1 allo-
morphs in complex with HLA-B*57:01. 
(A) Two conformations of the C–C′ loop 
of KIR3DL1 are present in complex with 
HLA-B*57:01. The loop as observed in the 
KIR3DL1*001 complex is colored orange, and 
the conformation as observed in *005/*015 
is colored blue. (B and D) The structural 
consequences surrounding the site of the 
KIR3DL1 W283L dimorphism at the D1–D2 
interface. The conformation as observed in 
KIR3DL1*001/*015 is shown in B. The con-
formation as observed in KIR3DL1*005 is 
shown in D. (C) Subtle differences at positions 
Met165 and His278 differentiate the binding 
of KIR3DL1*001 and *005. The conformation 
as observed in KIR3DL1*001/*015 is colored 
orange, whereas the conformation as observed 
in *005 is colored cyan.
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HLA-associated peptide, it is unclear whether this synergism 
was a general feature of ligand recognition by these allotypes 
(Malnati et al., 1995; Thananchai et al., 2007). Regardless, that 
polymorphisms distal to the HLA-binding interface are able 
to impact ligand binding avidity implies an indirect molec-
ular mechanism. Several studies have noted such effects, par-
ticularly from allotypes bearing polymorphisms at residues 
58, 92, and 238 (Carr et al., 2005; Thananchai et al., 2007; 
Mulrooney et al., 2015). Interestingly, our data analyzing the 
structures of KIR3DL1*001, *005, and *015 identified two 
conformations of the D0–D1 domains. However, these dif-
fering docking conformations were not wholly attributable 
to KIR3DL1 polymorphisms as different docking angles have 
been observed between KIR3DL1*001 and HLA-B*57:01 
in complex with different peptides (unpublished data). This 
indicates that there is a degree of flexibility across the three 
KIR3DL1 domains whose ultimate arrangement, though in 
part regulated by polymorphic residues that are spatially re-
mote from the ligand-binding site, are also subject to the na-
ture of the HLA allotype and the associated peptide.
The structural data show that the Leu-Trp dimorphism 
at position 283 is associated with an altered juxtapositioning of 
the D1 and D2 domains, resulting in a subtle realignment of the 
residues contacting the HLA-B*57:01–LF9 complex. More-
over, the deuterium exchange data revealed that the larger hinge 
angle associated with the presence of Leu283 confers a degree 
of flexibility, particularly over the KIR3DL1 loops, which are 
intimately involved in recognition of both the peptide and the 
Bw4 motif. These findings suggest that the increased flexi-
bility of the ligand-binding region allows KIR3DL1*005 to 
better accommodate variability in the sequence of peptides 
bound to Bw4 allotypes. Consistent with this notion, the in-
troduction of Leu283 into both KIR3DL1*001 and *015 
substantially enhanced binding to HLA-B*57:01 complexed 
with an escape variant of the HIV-encoded peptide TW10 
(O’Connor et al., 2014).
Predicting the functional outcomes that result from 
KIR3DL1–HLA-I interactions is complex and is likely based on 
the conjoined effects of avidity and surface expression of both 
receptor and ligand, as well as cell surface clustering and the sig-
naling potential of the receptor (Pando et al., 2003; Carr et al., 
2005; Mulrooney et al., 2015). Although it is clear that several 
polymorphisms in KIR3DL1 can impact functional responses to 
cells bearing HLA-Bw4 molecules, our study has elucidated the 
effect of polymorphisms within the two major KIR3DL1 lin-
eages that combine to influence binding avidity and ultimately 
specificity. Accordingly, we have demonstrated distinct recogni-
tion hierarchies and identified a broad conceptual framework to 
understand the impact of polymorphism across the KIR3DL1–
HLA-I axis that will result in an improved understanding of 
KIR3DL1/HLA pairings in disease and transplant settings.
MAT ERI ALS AND MET HODS
Cell lines. The human HLA-Ia–deficient B-lymphoblastoid cell 
line 721.221 (221) was transfected with HLA-A*24:02, HLA-
B*08:01, HLA-B*27:05, HLA-B*44:05, or HLA-B*57:01 via 
electroporation at 200 V and 975 µF (Saunders et al., 2015). 
221.B58 cells were a gift from P. Parham (Stanford Univer-
sity, Stanford, CA). All cells were maintained in RPMI 1640 
medium (Lonza) supplemented with antibiotics and 10% FBS.
Purification of NK cells and generation of KIR3DL1+ NK cell 
clones. Human PBMCs were isolated from healthy blood 
donors by Ficoll/Hypaque density gradient centrifugation. 
Negative selection of untouched NK cells was performed 
using RosetteSep or EasySep Human NK Cell Enrichment 
kits (STE MCE LL Technologies) according to the manu-
facturer’s instructions. NKG2A−KIR3DL1+ (Z199−DX9+) 
cells were isolated by flow cytometry at >95% purity using 
a FAC SAria II (BD). KIR3DL1+ NK cells were cultured 
on irradiated feeder cells in the presence of 100 U/ml 
rhIL-2 (Proleukin; Chiron Corp.) and 1.5 ng/ml PHA (Gibco) 
and cloned by limiting dilution. Proliferating NK cell clones 
were analyzed for KIR3DL1 expression and the absence of 
NKG2A (Z270) before use in functional experiments. NK 
cells were maintained in RPMI 1640 supplemented with an-
tibiotics, 10% FBS, and 100 U/ml IL-2. For donors with an 
unknown KIR3DL1 allele, the expressed KIR3DL1 mole-
cule was sequenced from extracted RNA (Saunders et al., 
2015). All experiments were performed in accordance with 
approvals from the Human Research Ethics Committee, Uni-
versity of Melbourne, or the Liguria Regional Committee.
NK cell cytotoxicity. NK cell–mediated cytotoxicity was as-
sessed in standard 4-h chromium release assays (Pende et al., 
2009). In brief, effector cells were incubated with 51Cr- 
labeled 221 transfectants at various effector/target (E:T) ra-
tios. For masking experiments, KIR3DL1+ NK cell clones 
were incubated with 51Cr-labeled target cells, either in cul-
ture medium alone or in the presence of an anti-KIR3DL1/
S1 mAb (clone Z27, IgG1) at a concentration of 10 µg/ml. 
Data were normalized to the maximal lysis of parental 221 
target cells detected in the absence of Z27 blocking.
CD107a assay. NK cells and 221 transfectants were mixed at 
a 1:1 ratio and incubated for 1  h in the presence of anti- 
Figure 6. KIR3DL1*005 displays greater molecular mobility across three ligand-binding loops. (A–F) Hydrogen–deuterium exchange of peptidic 
fragments from KIR3DL1. Representative m/z spectra of each peptidic fragment after 30 s are shown for each KIR3DL1*015 (yellow), *001 (orange), and 
*005 (blue) and at time 0 s (magenta). Bar graphs show the extent of deuterium exchange for each KIR3DL1 allomorph plotted at time points 0, 10, and 
30 s. (A–C) Peptidic fragments derived from the KIR3DL1 D1 and D1–D2 linker. (D–F) Peptidic fragments derived from the KIR3DL1 D2. Data are from three 
independent experiments (each time point in triplicate). Error bars depict SEM.
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CD107a-PE (BD) before the addition of monensin. The 
blocking antibody Y9 was added to NKG2A+ NK cells before 
mixing with targets. After a further 3-h incubation, cells were 
stained with anti-NKB1-FITC (anti-KIR3DL1; BD) and an-
ti-CD56-APC (BD), fixed in 2% paraformaldehyde, and ana-
lyzed by flow cytometry. The percentage of KIR3DL1+ NK 
cells expressing CD107a was determined using FlowJo soft-
ware (Tree Star) and normalized to maximal CD107a expres-
sion in the presence of parental 221 target cells.
Cloning and expression of KIR3DL1. The extracellular domains 
of KIR3DL1*001/*005/*015 (residues 1–299) were sub-
cloned into vectors for insect cell and mammalian cell expres-
sion. For insect cell expression, the genes were subcloned into 
a modified baculoviral pFastBac-expression vector (Invitrogen) 
containing a secretion signal peptide sequence, an N-terminal 
hexa-histidine tag, and a C-terminal BirA tag (Stifter et al., 
2014). For mammalian expression, the genes were subcloned 
into the pHLSec expression vector containing a secretion sig-
nal peptide sequence and an N-terminal hexa-histidine tag 
(Aricescu et al., 2006). Insect cell expression of KIR3DL1 was 
performed by baculoviral infection of BTI-TN-5B1-4 cells 
(Hi-5 cells; Invitrogen). Mammalian expression was performed 
by transient transfection of HEK293S GnTI− cells (Aricescu 
et al., 2006). From both cell lines, KIR3DL1 was secreted into 
the expression media and purified by binding to nickel Sep-
harose resin followed by size exclusion chromatography (S200 
16/60 column; GE Healthcare). The insect cell material was 
used for single-antigen bead experiments but was not amena-
ble to crystallization. The mammalian cell material was used in 
x-ray crystallography experiments after overnight incubation 
with endoglycosidase H (New England Biolabs, Inc.).
Bead assay. HLA-I recognition by KIR3DL1 allotypes was 
assessed through binding of KIR3DL1 tetramers to beads 
coated with a panel of 100 different HLA-A, -B, and -C mol-
ecules (LABScreen HLA Class I Single Antigen; One Lambda). 
PE-conjugated KIR3DL1 tetramer (5 µg per test) was incu-
bated with beads for 30 min at room temperature in the dark 
in 300 mM of phosphate-buffered NaCl (PBS-300) with 5% 
fetal calf serum (AusGeneX). The beads were then washed 
three times in PBS-300 with 0.05% Tween 20 and resuspended 
in PBS-300. Binding was measured on a Luminex platform 
(LABScan 100; One Lambda) through identification of the 
individual HLA allotypes via unique bead labeling and detec-
tion of tetramer fluorescence intensity on each bead set. Nor-
malized fluorescence values for analysis were obtained using 
the HLA Fusion software suite (One Lambda) that subtracted 
background values using the following formula:
  ( S#N − SNC bead ) −  ( BG#N − BGNC bead ) , 
where S#N is the sample-specific fluorescence value 
(trimmed mean) for bead #N, SNC bead is the sam-
ple-specific fluorescence value for the negative control 
(nude) bead, BG#N is the background negative control 
fluorescence value for bead #N, and BGNC bead is the 
background negative control fluorescence value for nega-
tive control bead. To obtain binding values for each HLA-
I, mean fluorescence intensity (MFI) values for an isotype 
control (a PE-conjugated IgG) were subtracted from the 
raw values obtained for each experiment, and recognition 
was assessed as being higher than that of the tetramer to 
beads without conjugated HLA-I. MFI values were nor-
malized to the highest value for each experiment and then 
averaged over three experiments.
Expression and purification of HLA-B*57:01. Plasmids en-
coding HLA-B*57:01 and β2-microglobulin were expressed 
separately in Escherichia coli and refolded in the presence 
of the peptide LF9. Purification of the HLA-B*57:01–
LF9 complex was performed as described previously 
(Chessman et al., 2008).
Crystallization, data collection, structure determination, 
and refinement. KIR3DL1*005 and *015 expressed in 
mammalian HEK 293S GnTI− cells were concentrated to 
12 mg/ml and combined with HLA-B*57:01–LF9 at a 
1:1 molar ratio. The KIR3DL1–peptide–HLA-B*57:01 
complexes were crystallized at 294K by the hanging-
drop vapor-diffusion method from a solution comprising 
14–18% PEG 3350, 2% Tacsimate, pH 5.0, and 0.1 M tri-
sodium citrate, pH 5.6. Before data collection, the crystals 
were equilibrated in crystallization solution with 35% 
PEG 3350 added as a cryoprotectant and then flash-cooled 
in a stream of liquid nitrogen at 100K. X-ray diffraction 
data were collected at the MX2 beamline (Australian 
Synchrotron). The data were recorded on a Quantum-315 
CCD detector and were integrated and scaled using 
MOS FLM and SCA LA from the CCP4 program suite 
(Collaborative Computational Project, Number 4, 1994; 
Evans, 2006). Details of the data processing statistics 
are summarized in Table  1. The crystal structures were 
determined by molecular replacement, as implemented in 
PHA SER (McCoy et al., 2007), with KIR3DL1*001–LF9–
HLA-B*57:01 used as the search model (Protein Data Bank 
accession no. 3VH8 [Vivian et al., 2011]). Refinement of the 
models proceeded with iterative rounds of manual building 
in Coot (Emsley and Cowtan, 2004) and refinement in 
PHE NIX (Adams et al., 2010). The final models comprised 
N-acetylglucosamine groups at Asn71, Asn158, and Asn252. 
The structures were validated with MOL PRO BITY (Chen 
et al., 2010). Refinement statistics are summarized in 
Table 1. Coordinates and structure factors were deposited in 
the Protein Data Bank (KIR3DL1*005–HLA -B57 :01–LF9, 
5B38; KIR3DL1*015–HLA -B57 :01–LF9, 5B39).
Peptide mapping by HPLC–tandem mass spectrometry. Pep-
tide mapping was performed as described previously (Tsutsui 
et al., 2006). In brief, 5 µg of purified KIR3DL1 (in 100 µl of 
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100 mM Tris, pH 7.4, and 80 mM NaCl) was mixed with 
95 µl of 0.5% TFA, pH 2.4. 5 µg porcine pepsin dissolved in 
0.05% (vol/vol) TFA was then added over 5 min on ice. The 
digested sample was injected into a micropeptide trap (Grace) 
connected to a Everest C18 column (50 mm × 1 mm, 5 µm; 
Grace) and a micrOTOF mass spectrometer (Bruker). Pep-
tidic fragments were eluted with a gradient of acetonitrile at 
a flow rate of 50 µl/min for tandem mass spectrometry to 
sequence each peptidic fragment. Peptidic fragments were 
identified using the Mascot search algorithm.
Hydrogen deuterium exchange analyses. Soluble KIR3DL1 
(in 100 mM Tris, pH 7.4, and 50 mM NaCl) was diluted 24-
fold in 100 mM Tris, pH 7.4, and 80 mM NaCl dissolved in 
D2O (Cambridge Isotope Laboratories) at 25°C. The reaction 
was quenched at different time points by adding an equal 
volume of 0.5% TFA, pH 2.4, followed by rapid freezing. The 
first experimental time point was measured 10 s after initia-
tion of the experiment. Frozen samples were thawed and di-
gested with 5 µg pepsin on ice for 5 min and then injected 
immediately into a micropeptide trap connected to a C18 
column and a micrOTOF mass spectrometer. Peptides were 
eluted in 12 min using a gradient of 10–45% acetonitrile at a 
flow rate of 50 µl/min. The micropeptide trap and C18 col-
umn were immersed in ice to minimize back exchange. To 
correct for any back exchange of hydrogen atoms during 
pepsin digestion and HPLC-MS, a fully deuterated sample 
was prepared by incubating 5 µg KIR3DL1 in 6 M guanidine 
deuterochloride, 50 mM Tris, pH 8.0, and 50 mM NaCl for 
60 min at 25°C. The deuterium incorporation of each pep-
tidic fragment, corrected for the back exchange, was calcu-
lated using the following equation: D/N = [(m − m0%)/
(m100% − m)], where m is the mass of deuterated peptidic 
fragment, m0% and m100% are the mass of the unlabeled and 
fully deuterated peptidic fragments, respectively, N is the total 
number of exchangeable amide hydrogen atoms in each pep-
tidic fragment, and D is the number of amide hydrogen atoms 
incorporated in each peptide.
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